New vaccine trial aims to shield teens and adults from whooping cough
NCT ID NCT07492303
First seen Mar 25, 2026 · Last updated Jun 19, 2026 · Updated 15 times
Summary
This early-stage trial is testing a new combination vaccine that protects against whooping cough, diphtheria, and tetanus (Tdap) in people aged 10 and older. Researchers want to see if different doses are safe and trigger an immune response. The study involves 96 volunteers and compares the vaccine to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETANUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tdap vaccine (acellular pertussis, diphtheria, tetanus combined)
What this could lead to
If successful, this could lead to a new, safe vaccine option to protect adolescents and adults from whooping cough, diphtheria, and tetanus.
What could go wrong
This is an early Phase 1 trial with only 96 participants, so it's too soon to know if the vaccine works. The main goal is safety, and unexpected side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.